Thromb Haemost 2018; 118(08): 1470-1480
DOI: 10.1055/s-0038-1666870
Atherosclerosis and Ischaemic Disease
Georg Thieme Verlag KG Stuttgart · New York

Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R−/−) Mice

Renata Feuerborn*
1   Center for Laboratory Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Manuela Besser*
2   Department of Anaesthesiology and Intensive Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Francesco Potì
3   Department of Medicine and Surgery–Unit of Neurosciences, University of Parma, Parma, Italy
4   Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
,
Ralph Burkhardt
5   Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, University of Leipzig, Leipzig, Germany
,
Gabriele Weißen-Plenz
1   Center for Laboratory Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Uta Ceglarek
5   Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, University of Leipzig, Leipzig, Germany
,
Manuela Simoni
4   Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
,
Richard L. Proia
6   Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States
,
Hendrik Freise
2   Department of Anaesthesiology and Intensive Medicine, University Hospital Münster, University of Münster, Münster, Germany
,
Jerzy-Roch Nofer
1   Center for Laboratory Medicine, University Hospital Münster, University of Münster, Münster, Germany
› Author Affiliations
Funding Grant NO406/3–1 from Deutsche Forschungsgemeinschaft (DFG) to J.-R.N., grant NO110816 from the Innovative Medizinische Forschung (IMF) to J.-R.N., intramural resources of the Center for Laboratory Medicine to J.-R.N., FIRB-IDEAS grant RBID08777T from the Italian Ministry of Education, University and Research to J.-R.N. and M.S. and the Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease to R.P.
Further Information

Publication History

16 January 2018

24 May 2018

Publication Date:
30 July 2018 (online)

Abstract

Background Sphingosine-1-phosphate (S1P) is a bioactive lysosphingolipid and a constituent of high-density lipoprotein (HDL) exerting several atheroprotective effects in vitro. However, the few studies addressing anti-atherogenic effects of S1P in vivo have led to disparate results. We here examined atherosclerosis development in low-density lipoprotein receptor (LDL-R)-deficient (LDL-R−/−) mice with elevated endogenous S1P levels.

Methods and Results Sub-lethally irradiated LDL-R−/− mice were transplanted with bone marrow deficient in sphingosine kinase 2 (SphK2), which led to the elevation of S1P concentrations in erythrocytes, plasma and HDL by approximately 1.5- to 2.0-fold in SphK2−/−/LDL-R−/− mice. Afterwards, mice were fed a Western diet for 14 weeks. Elevation of endogenous S1P significantly reduced atherosclerotic lesion formation by approximately half without affecting the plasma lipid profile. Furthermore, the macrophage content of atherosclerotic lesions and lipopolysaccharide-induced monocyte recruitment to the peritoneal cavity were reduced in SphK2−/−/LDL-R−/− mice. Studies using intra-vital microscopy revealed that endogenous S1P lowered leukocyte adhesion to capillary wall and decreased endothelial permeability to fluorescently labelled LDL. Moreover, SphK2−/−/LDL-R−/− mice displayed decreased levels of vascular cell adhesion molecule 1 in atherosclerotic lesions and in plasma. Studies in vitro demonstrated reduced monocyte adhesion and transport across an endothelial layer exposed to increasing S1P concentrations, murine plasma enriched in S1P or plasma obtained from SphK2-deficient animals. In addition, decreased permeability to fluorescence-labelled dextran beads or LDL was observed in S1P-treated endothelial cells.

Conclusion We conclude that raising endogenous S1P levels exerts anti-atherogenic effects in LDL-R−/− mice that are mediated by favourable modulation of endothelial function.

* Renata Feuerborn and Manuela Besser contributed equally to this study.


Supplementary Material

 
  • References

  • 1 Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest 2015; 125 (04) 1379-1387
  • 2 Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog Lipid Res 2016; 62: 93-106
  • 3 Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 2011; 111 (10) 6299-6320
  • 4 Xiong Y, Hla T. S1P control of endothelial integrity. Curr Top Microbiol Immunol 2014; 378: 85-105
  • 5 Wilkerson BA, Argraves KM. The role of sphingosine-1-phosphate in endothelial barrier function. Biochim Biophys Acta 2014; 1841 (10) 1403-1412
  • 6 Bolick DT, Srinivasan S, Kim KW. , et al. Sphingosine-1-phosphate prevents tumor necrosis factor-α-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol 2005; 25 (05) 976-981
  • 7 Kimura T, Tomura H, Mogi C. , et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006; 281 (49) 37457-37467
  • 8 Schuchardt M, Tölle M, Prüfer J, van der Giet M. Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br J Pharmacol 2011; 163 (06) 1140-1162
  • 9 Tölle M, Pawlak A, Schuchardt M. , et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28 (08) 1542-1548
  • 10 Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 2013; 1831 (01) 203-212
  • 11 Abbasi T, Garcia JG. Sphingolipids in lung endothelial biology and regulation of vascular integrity. Handb Exp Pharmacol 2013; 216 (216) 201-226
  • 12 Christoffersen C, Nielsen LB. Apolipoprotein M: bridging HDL and endothelial function. Curr Opin Lipidol 2013; 24 (04) 295-300
  • 13 Karuna R, Park R, Othman A. , et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011; 219 (02) 855-863
  • 14 Argraves KM, Sethi AA, Gazzolo PJ. , et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011; 10: 70
  • 15 Sattler K, Gräler M, Keul P. , et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol 2015; 66 (13) 1470-1485
  • 16 Potì F, Simoni M, Nofer JR. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovasc Res 2014; 103 (03) 395-404
  • 17 Levkau B. HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front Pharmacol 2015; 6: 243
  • 18 Potì F, Gualtieri F, Sacchi S. , et al. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice. Arterioscler Thromb Vasc Biol 2013; 33 (07) 1505-1512
  • 19 Nofer JR, Bot M, Brodde M. , et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115 (04) 501-508
  • 20 Keul P, Tölle M, Lucke S. , et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27 (03) 607-613
  • 21 Galvani S, Sanson M, Blaho VA. , et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal 2015; 8 (389) ra79
  • 22 Gonzalez L, Qian AS, Tahir U, Yu P, Trigatti BL. Sphingosine-1-phosphate receptor 1, expressed in myeloid cells, slows diet-induced atherosclerosis and protects against macrophage apoptosis in LDLR KO mice. Int J Mol Sci 2017; 18 (12) E2721
  • 23 Skoura A, Michaud J, Im DS. , et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31 (01) 81-85
  • 24 Bosteen MH, Madsen Svarrer EM, Bisgaard LS. , et al. Effects of apolipoprotein M in uremic atherosclerosis. Atherosclerosis 2017; 265: 93-101
  • 25 Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25 (24) 11113-11121
  • 26 Ceglarek U, Dittrich J, Helmschrodt C. , et al. Preanalytical standardization of sphingosine-1-phosphate, sphinganine-1-phosphate and sphingosine analysis in human plasma by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2014; 435: 1-6
  • 27 Poti F, Bot M, Costa S. , et al. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice. Thromb Haemost 2012; 107 (03) 552-561
  • 28 Eschert H, Sindermann JR, Scheld HH, Breithardt G, Weissen-Plenz G. Vascular remodeling in ApoE-deficient mice: diet dependent modulation after carotid ligation. Atherosclerosis 2009; 204 (01) 96-104
  • 29 Nitschke Y, Weissen-Plenz G, Terkeltaub R, Rutsch F. Npp1 promotes atherosclerosis in ApoE knockout mice. J Cell Mol Med 2011; 15 (11) 2273-2283
  • 30 Sensken SC, Bode C, Nagarajan M, Peest U, Pabst O, Gräler MH. Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J Immunol 2010; 184 (08) 4133-4142
  • 31 Bot M, Van Veldhoven PP, de Jager SC. , et al. Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice. PLoS One 2013; 8 (05) e63360
  • 32 Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013; 13 (10) 709-721
  • 33 Hedrick CC. Lymphocytes in atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35 (02) 253-257
  • 34 Xiong Y, Lee HJ, Mariko B. , et al. Sphingosine kinases are not required for inflammatory responses in macrophages. J Biol Chem 2013; 288 (45) 32563-32573
  • 35 Maiuri MC, Grassia G, Platt AM, Carnuccio R, Ialenti A, Maffia P. Macrophage autophagy in atherosclerosis. Mediators Inflamm 2013; 2013: 584715
  • 36 Kimura T, Tomura H, Mogi C. , et al. Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal 2006; 18 (06) 841-850
  • 37 Kimura T, Mogi C, Tomura H. , et al. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol 2008; 181 (10) 7332-7340
  • 38 Shimizu H, Takahashi M, Kaneko T. , et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005; 111 (02) 222-229
  • 39 Kaneko T, Murakami T, Kawana H, Takahashi M, Yasue T, Kobayashi E. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun 2006; 345 (01) 85-92
  • 40 Ogawa R, Takahashi M, Hirose S. , et al. A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. Biochem Biophys Res Commun 2007; 361 (03) 621-628
  • 41 Zhang ZY, Zhang Z, Zug C, Nuesslein-Hildesheim B, Leppert D, Schluesener HJ. AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 2009; 216 (1-2): 59-65
  • 42 Bajwa A, Jo SK, Ye H. , et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 2010; 21 (06) 955-965
  • 43 Christensen PM, Bosteen MH, Hajny S, Nielsen LB, Christoffersen C. Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes. Sci Rep 2017; 7 (01) 14983
  • 44 Christensen PM, Liu CH, Swendeman SL. , et al. Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1. FASEB J 2016; 30 (06) 2351-2359
  • 45 Ruiz M, Frej C, Holmér A, Guo LJ, Tran S, Dahlbäck B. High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1. Arterioscler Thromb Vasc Biol 2017; 37 (01) 118-129
  • 46 Ruiz M, Okada H, Dahlbäck B. HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium. Lipids Health Dis 2017; 16 (01) 36